Effectiveness of preeclampsia prognosis in pregnancy.
DOI:
https://doi.org/10.26641/2307-0404.2014.1.24703Ключові слова:
pregnancy, pre-eclampsia, gene polymorphism, hemostasis, antiphospholipid antibodies, prognosis, probability, risk groupАнотація
With the purpose to develop and assess the effectiveness of prediction method of pre-eclampsia (PE) 177 women in III trimester of pregnancy were examined. Of them: 133 women with preeclampsia of varying severity, 44 - with uncomplicated pregnancy. Prediction method is based on testing of thrombophilia genes, level of antibodies to β2 glycoprotein-1, D-dimer, value of atherogenicity coefficient. Using maximum likelihood method risk function was designed and formula which allows to estimatie probability of pre-eclampsia development was made. For practical applications, a graphical representation of likelihood of pre-eclampsia development from the calculated risk function is given. The sensitivity of the proposed model is 82,5% (95% CI 74,2-88,9%), specificity – 90,9% (95% CI 78,3-88,9%). To evaluate the effectiveness this prediction method was tested on a group of 108 pregnant women who were tested in the first trimester. 84 pregnant women were in the group with the predicted low risk (P(y)<0,683) and 24 in the group with a predicted high risk (P (y)≥0,683) of pre-eclampsia development. Analyzing the effectiveness of a prediction method it was proved that in the group with predicted high risk of PE absolute risk of preeclampsia increased by 54.7% (95% CI 50,3-59,08), PE of mild severity – by 21,34% (95% CI 16,75-25,92), PE of moderate severity – by 33,33% (95% CI 28,7-37,9), preterm delivery – by 30,86% (95% CI 41,8-50,57), cesarean section in preterm labor and placenta abruption – by 9,5% (95% CI 4,8-14,2 ), fetal distress during labor – by 14,3% (95% CI 9,6-18,97), perinatal losses by 14.2% (95% CI 9,6-18,97), fetal growth retardation – by 42,9% (95% CI 38,3-47,4), the need for neonatal intensive care – by 26,1% (95% CI 21,5-30,6). Practical use of the proposed model allows to identify pregnant women with high risk of pre-eclampsia, to conduct preventive measures, to review plan of prenatal care as for timely hospitalization and to determine fetus state.Посилання
Макацария А.Д. Тромбофилии и противотромботическая терапия в акушерской практике / А.Д. Макацария, В.О. Бицадзе.-М.: Триада Х, 2003. – 904 с.
Оксидативный стресс в генезе акушерских осложнений / Л.В. Ванько, В.Г. Сафронова, Н.К. Мат¬ве¬ева, Г.Т. Сухих. – М.: ГЭОТАР-Медиа, 2010. – 264с.
Определение наследственной предрасположенности к некоторым частым заболеваниям при беременности: метод. рекомендации / В.С. Баранов, Т.Э. Иващенко, А.С. Глотов [и др.]; под ред. В.С. Ба¬ранова и Э.К. Айламазяна. – СПб.: Изд-во «Н-Л», 2009. – 68 с.
Про затвердження клінічних протоколів з акушерської та гінекологічної допомоги: Наказ від 31.12.2004 р. / Міністерство охорони здоров’я Украї¬ни. – К., 2004. – № 676.
Риски и их оценка в медико-биологических исследованиях: метод. рекомендации / С.А. Максимов, С.Ф. Зинчук, Е.А. Давыдова, В.Г. Зинчук. – Кемерово, 2010. – 28 с.
Роль молекулярно-генетичеких факторов тромбофилии в развитии преэклампсии у женщин восточного региона Украины / В.К. Чайка, Е.Н. Но¬сенко, Б. Мертил [и др.] // Таврич. мед.-биол. вестник. – 2010. – Т. 148, №3. – С.222-224.
Турчин В.Н. Теория вероятностей и математическая статистика. Основные понятия, примеры и задачи / В.Н. Турчин. – Днепропетровск: ИМА-ПРЕСС, 2012. – 576 с.
-455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications / R.C. Camilleri, D. Peebles, C. Portmann [et al.] // Blood Coagulation Fibrinolysis. – 2004. – Vol. 15, N 2. – Р.139-147.
Brenner B. Thrombophilia and pregnancy compli¬cations / B. Brenner // Pathophysiol. Haemost. Thromb. – 2006 – Vol. 35, N 1-2 – P. 28-35.
Pathophysiology of hypertension in pre-eclam¬psia: a lesson in integrative physiology / А.С. Palei, F.T. Spradley, J.P. Warrington [et al.] // Acta. Physiol. – 2013. – Vol 208, N 4. – P. 224-233.
Relationship between thrombophilic disorders and type of severe early hypertensive disorders of pregnancy / W.Ganzevoort, A. Rep, J.I. DeVries [et al.] // Hypertens. Pregnancy. – 2007.–Vol. 26, N 4 –P. 433-445.
Makatsariya AD, Bitsadze VO. [Thrombophilia and antithrombotic therapy in obstetric practice]. M.: Triada Kh. 2003; 904 p. Russian.
Van'ko LV, Safronova VG, Matveeva NK, Sukhikh GT. [Oxidative stress in the genesis of obstetric complications]. M.: GEOTAR-Media. 2010; 264 p. Russian.
Baranov VS, Ivashchenko TE, Glotov AS. [Determination of genetic predisposition to certain diseases common in pregnancy: guidelines]. SPb.: «Iz-vo N-L». 2009; 68 p. Russian.
[On approval of clinical protocols for obstetric and gynecological care: Order of 31.12.2004 № 676]. Mіnіsterstvo okhoroni zdorov’ya Ukraїni. K; 2004. Ukrainian.
Maksimov SA, Zinchuk SF, Davydova EA, Zinchuk VG. [Risks and their evaluation in biomedical research: guidelines].– Kemerovo, 2010; 28 p. Russian.
Chayka VK, Nosenko EN, Mertil B. [The role of molecular genetic factors of thrombophilia in the development of preeclampsia, in women of eastern region of Ukraine]. Tavr. med.-biol. vestnik. 2010;148(3):222-224. Russian.
Turchin VN. [Probability theory and mathematical statistics. Basic concepts, examples and problems]. Dnepropetrovsk: IMA-PRESS. 2012; 576 p. Russian.
Camilleri RC, Peebles D, Portmann C. -455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications. Blood Coagulation Fibrinolysis. 2004;15 (2):139-147.
Brenner B. Thrombophilia and pregnancy compli¬cations. Pathophysiol. Haemost. Thromb. 2006; 35(1-2): 28-35.
Palei АС, Spradley FT, Warrington JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta. Physiol. 2013; 208 (4): 224-233.
Ganzevoort W, Rep A, DeVries JI. Relationship between thrombophilic disorders and type of severe early hypertensive disorders of pregnancy. Hypertens. Pregnancy. 2007; 26 (4): 433-445
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2017 Медичні перспективи
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
